A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

NCT05566990 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

BIOLOGICAL: LIV-GAMMA SN Inj.10%

Sponsor

SK Plasma Co., Ltd.